Retrospective Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2018; 10(1): 31-39
Published online Jan 15, 2018. doi: 10.4251/wjgo.v10.i1.31
Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer
Qi-Wei Wang, Xiao-Tian Zhang, Ming Lu, Lin Shen
Qi-Wei Wang, Medical Oncology, Department of Gastrointestinal Cancer, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China
Xiao-Tian Zhang, Ming Lu, Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China
Author contributions: Wang QW drafted the article and contributed to data processing; Zhang XT and Shen L designed research and contributed to the statistical assessment; Lu M participated in the clinical assessment of the cases.
Institutional review board statement: This clinical research report submitted by Dr Xiaotian Zhang. The investigation project has been examined and certified by Ethics Committee of Beijing Cancer Hospital on July 1, 2015.
Informed consent statement: Due to the retrospective nature of the study, informed consent was waived by the Ethics Committee of Beijing Cancer Hospital committee.
Conflict-of-interest statement: The author declare that they have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Xiao-Tian Zhang, MD, Professor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. zhangxiaotianmed@126.com
Telephone: +86-10-88196561 Fax: +86-10-88196561
Received: September 6, 2017
Peer-review started: September 7, 2017
First decision: October 9, 2017
Revised: November 24, 2017
Accepted: December 13, 2017
Article in press: December 13, 2017
Published online: January 15, 2018
Processing time: 128 Days and 7.4 Hours
Core Tip

Core tip: Patients with T4bN1-3M0/TxN3bM0 gastric cancer have a poor prognosis after curative resection. Due to limited evidence and a lack of guidelines for clinical practice, T4bN1-3M0/TxN3bM0 gastric cancer remains a challenging clinical problem. Our retrospective study is complementary to large-scale phase III prospective trials and showed that the most common pattern of first recurrence for this population is distant metastasis and that prolonged adjuvant chemotherapy may improve patient outcomes. This finding will need to be confirmed by future prospective randomized controlled studies to improve the outcomes for patients with T4bN1-3M0/TxN3bM0 gastric cancer.